Cost-Related Antihypertensive Medication Nonadherence: Action in the Time of COVID-19 and Beyond.
作者信息
Tajeu Gabriel S, Muntner Paul
机构信息
Department of Health Services Administration and Policy, Temple University, Philadelphia, Pennsylvania, USA.
Department of Epidemiology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
出版信息
Am J Hypertens. 2020 Sep 10;33(9):816-818. doi: 10.1093/ajh/hpaa085.
Abstract
摘要
相似文献
1
Cost-Related Antihypertensive Medication Nonadherence: Action in the Time of COVID-19 and Beyond.
Am J Hypertens. 2020 Sep 10;33(9):816-818. doi: 10.1093/ajh/hpaa085.
2
Antihypertensive treatment with ACEI/ARB of patients with COVID-19 complicated by hypertension.
Hypertens Res. 2020 Jun;43(6):588-590. doi: 10.1038/s41440-020-0433-1. Epub 2020 Mar 30.
3
Switching antihypertensive therapy in times of COVID-19: why we should wait for the evidence.
Eur Heart J. 2020 May 14;41(19):1857. doi: 10.1093/eurheartj/ehaa335.
4
Antihypertensive drugs and risk of COVID-19?
Lancet Respir Med. 2020 May;8(5):e30-e31. doi: 10.1016/S2213-2600(20)30153-3. Epub 2020 Mar 26.
5
Antihypertensive drugs and risk of COVID-19?
Lancet Respir Med. 2020 May;8(5):e29. doi: 10.1016/S2213-2600(20)30156-9. Epub 2020 Mar 26.
6
Antihypertensive drugs and risk of COVID-19?
Lancet Respir Med. 2020 May;8(5):e28. doi: 10.1016/S2213-2600(20)30158-2. Epub 2020 Mar 26.
7
Speculation is not evidence: antihypertensive therapy and COVID-19.
Eur Heart J Cardiovasc Pharmacother. 2020 Jul 1;6(3):133-134. doi: 10.1093/ehjcvp/pvaa021.
8
Antihypertensive drugs and risk of COVID-19? - Authors' reply.
Lancet Respir Med. 2020 May;8(5):e32-e33. doi: 10.1016/S2213-2600(20)30159-4. Epub 2020 Mar 26.
9
Renin-angiotensin system inhibitors in the COVID-19 pandemic: consequences of antihypertensive drugs.
Eur Heart J. 2020 Jun 7;41(22):2067-2069. doi: 10.1093/eurheartj/ehaa487.
10
[Arterial hypertension and COVID-19 infections: A brief commentary].
Vnitr Lek. 2020 Spring;66(3):104-106.
引用本文的文献
1
Leveraging a multifaceted digital medication refill system on improving patients' medication adherence and reducing medication oversupply among elderly patients with hypertension.
BMJ Open Qual. 2025 Jul 23;14(3):e002840. doi: 10.1136/bmjoq-2024-002840.
2
Review of Blood Pressure Control in Vulnerable Older Adults: The Role of Frailty and Sarcopenia.
J Vasc Dis. 2025 Jun;4(2). doi: 10.3390/jvd4020018. Epub 2025 May 14.
3
Sex-based disparities with cost-related medication adherence issues in patients with hypertension, ischemic heart disease, and heart failure.
J Am Med Inform Assoc. 2024 Dec 1;31(12):2924-2931. doi: 10.1093/jamia/ocae203.
4
Productivity-adjusted life-years and correlates of uncontrolled hypertension at two health facilities in Zambia.
PLoS One. 2023 Dec 7;18(12):e0295401. doi: 10.1371/journal.pone.0295401. eCollection 2023.
5
When blood pressure refuses to budge: exploring the complexity of resistant hypertension.
Front Cardiovasc Med. 2023 Jun 21;10:1211199. doi: 10.3389/fcvm.2023.1211199. eCollection 2023.
6
Adherence to antihypertensive treatment during the COVID-19 pandemic: findings from a cross-sectional study.
Clin Hypertens. 2022 Dec 1;28(1):35. doi: 10.1186/s40885-022-00219-0.
7
Cost-Effectiveness of Recommendations From the Surgeon General's Call-to-Action to Control Hypertension.
Am J Hypertens. 2022 Mar 8;35(3):225-231. doi: 10.1093/ajh/hpab162.
8
Using the Health Belief Model to Explain the Patient's Compliance to Anti-hypertensive Treatment in Three District Hospitals - Dar Es Salaam, Tanzania: A Cross Section Study.
East Afr Health Res J. 2021;5(1):50-58. doi: 10.24248/eahrj.v5i1.651. Epub 2021 Jun 11.
本文引用的文献
1
Association Between Cost-Related Medication Nonadherence and Hypertension Management Among US Adults.
Am J Hypertens. 2020 Sep 10;33(9):879-886. doi: 10.1093/ajh/hpaa072.
2
Intersecting U.S. Epidemics: COVID-19 and Lack of Health Insurance.
Ann Intern Med. 2020 Jul 7;173(1):63-64. doi: 10.7326/M20-1491. Epub 2020 Apr 7.
3
Potential US Population Impact of the 2017 ACC/AHA High Blood Pressure Guideline.
Circulation. 2018 Jan 9;137(2):109-118. doi: 10.1161/CIRCULATIONAHA.117.032582. Epub 2017 Nov 13.
4
Systolic Blood Pressure Reduction and Risk of Cardiovascular Disease and Mortality: A Systematic Review and Network Meta-analysis.
JAMA Cardiol. 2017 Jul 1;2(7):775-781. doi: 10.1001/jamacardio.2017.1421.
5
Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association.
Circulation. 2017 Mar 7;135(10):e146-e603. doi: 10.1161/CIR.0000000000000485. Epub 2017 Jan 25.
6
Vital Signs: Disparities in Antihypertensive Medication Nonadherence Among Medicare Part D Beneficiaries - United States, 2014.
MMWR Morb Mortal Wkly Rep. 2016 Sep 16;65(36):967-76. doi: 10.15585/mmwr.mm6536e1.
7
Reducing Medication Costs to Prevent Cardiovascular Disease: A Community Guide Systematic Review.
Prev Chronic Dis. 2015 Nov 25;12:E208. doi: 10.5888/pcd12.150242.
8
Improving Adherence to Therapy and Clinical Outcomes While Containing Costs: Opportunities From the Greater Use of Generic Medications: Best Practice Advice From the Clinical Guidelines Committee of the American College of Physicians.
Ann Intern Med. 2016 Jan 5;164(1):41-9. doi: 10.7326/M14-2427. Epub 2015 Nov 24.
9
Recent trends in the dispensing of 90-day-supply prescriptions at retail pharmacies: implications for improved convenience and access.
Am Health Drug Benefits. 2011 Mar;4(2):95-100.
10
Medication days' supply, adherence, wastage, and cost among chronic patients in Medicaid.
Medicare Medicaid Res Rev. 2012 Sep 19;2(3). doi: 10.5600/mmrr.002.03.a04. eCollection 2012.
Zotero 插件